PACB•benzinga•
Sequencing Company PacBio Cuts Costs Amid Uncertainty Around NIH Funding And New Tariffs
Summary
PacBio reaffirms 2025 revenue outlook and unveils cost-cutting measures as Vega system demand grows and Revio usage meets expectations.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 9, 2025 by benzinga